Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?

Cancer Clinical Trial Compensation: Undue or Long Overdue?

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604

University of California, Davis, Thoracic Oncology Innovation Group to Again Host Latin American Oncologists for 3-Day Preceptorship 

Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring

Supporting the Detection of Early-Stage Disease with Use of Biomarkers

Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery

ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy

Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy

FDA Perspectives on the Use of Liquid Biopsy in NSCLC